Abstract: Provided is a proton-conducting compound which provides proton conductivity without humidification and is suitable for electrochemical device materials such as solid electrolytes for fuel cells and electrolytes for batteries. Provided also is a proton-conducting polymer. The proton-conducting compound is composed of a melamine compound salt obtained from a melamine compound represented by the following formula (1) and a Bronsted acid and the proton-conducting polymer is obtained by homopolymerizing or copolymerizing the melamine compound salt. In formula (1), R1, R2, R3, R4, and R5 each is independently an alkyl group, an aryl group, an alkenyl group, a heterocyclic group, or a hydrogen atom; at least one of them is a group other than hydrogen; R2 and R3 or R4 and R5 may join together to form a heterocyclic structure; and the alkyl group, the aryl group, the alkenyl group, or the heterocyclic group may have a substituent.

Abstract: Novel s-triazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or a related condition.

Abstract: Compounds of the formula (I) or salts thereof, in which in which R1 is an optionally substituted amino group or analogous group, and R2 to R7 are each as described herein, are suitable as herbicides and crop growth regulators. The compounds (I) can be prepared by the processes described, via intermediates including novel intermediates for example of the formula (III).

Abstract: The present invention provides, at least in part, compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, x, y, R2, R3, R4a, R4b, R5, R6 and R7 are described herein, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and their use as Aurora A kinase inhibitors in treatment, e.g., of cancer and other proliferative disorders.

Abstract: Methods of removing carbon dioxide comprising contacting a gas mixture comprising carbon dioxide with a sorbent. The sorbent comprises the following chemical structure: wherein at least one of R1, R2, and R3 comprises a primary amine group and wherein the sorbent is not melamine and does not comprise the following chemical structure: Sorbents for removing carbon dioxide are also disclosed.

Abstract: Compounds of formula (I) and (II) are disclosed, as well as methods for their identification, their preparation, pharmaceutical compositions containing them, and their use in treating disease. The compounds inhibit the production of TNF-alpha and interleukins (IL) by the inhibition of p38 kinase. They are useful in the treatment of inflammation and arthritis.

Abstract: Use of an affinity adsorbent for the separation, removal, isolation, purification, characterisation, identification or quantification of a proteinaceous material, wherein the affinity adsorbent is a compound of formula (III), wherein R1 is H, alkyl, aryl, hydroxyalkyl, cyciohexyl, amino or a heterocyclic group which is optionally substituted with one or more of alkyl, aryl, alkoxy, aryloxy, acyloxy, acylamino, amino, OH, CO2H, sulphonyl, carbamoyl, sulphamoyl, alkylsuiphonyl and halogen; one X is N and the other is N, C—Cl or C—CN; Y is O, S or NR2; Z is O, S or NR3; R2 and R3 are each H, alkyl, hydroxyalkyl, benzyl or ?-phenylethyl; Q is benzene, naphthalene, benzthiazole, benzoxazole, 1-phenylpyrazole, indazoie or benzimidazoie; R4, R5 and R6 are each H, OH, alkyl, aryl, heterocyclic, alkoxy, aryloxy, amino, acyloxy, acylamino, CO2H, sulphonic acid, carbamoyl, suiphamoyl, alkylsulphonyl or halogen, or two or more of R4, R5 and R6 are linked to form a cyclic structure; U and V are the same or different C1-10

Abstract: The present invention relates to a method for producing triazine carbamates by conversion of at least one triazine with at least one chloroformate in the presence of at least one alkaline or alkaline earth metal compound, wherein the alkaline or alkaline earth metal compound is not present in form of an alcoholate.

Abstract: Radiation-curable 1,3,5-triazine carbamates and 1,3,5-triazine ureas, processes for preparing them and their use.

Abstract: The invention relates to a process for preparing polymethylolated melamine and polymethylolated melamine compounds polyetherified with alkanol, wherein the methylolation reaction is carried out in a kneading reactor.

Abstract: The invention relates to a process for preparing free-flowing, pulverulent alkoxycarbonylaminotriazine from an alkanolic reaction mixture which is obtained in the preparation of alkoxycarbonylaminotriazines and comprises at least one alkoxycarbonylaminotriazine, at least one cyclic and/or acyclic carbonic ester, at least one C1-C13-alkanol which optionally comprises one or two oxygen atoms in the form of ether bonds and is optionally substituted by C1-C4-alkyl and/or hydroxyl, and also at least one alkali metal or alkaline earth metal alkoxide, with or without melamine and with or without catalyst, by atomizing and drying the reaction mixture in a spray drier.

Abstract: Compounds of formula (I) wherein R1 and R2 are the same or different and are each optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl groups; R3 is hydrogen or an aryl group substituent or R3 is a solid support optionally attached via a spacer; Z represents an oxygen atom, a sulphur atom or NR4; Y represents an oxygen atom, a sulphur atom or NR5; in which R4 and R5, which may be the same or different, represent hydrogen, optionally substituted alkyl containing 1 to 6 carbon atoms, optionally substituted phenyl, optionally substituted benzyl or optionally substituted ?-phenylethyl; and one of X1 and X2 represents a nitrogen atom and the other of X1 and X2 represents a nitrogen atom or CR6, in which R6 represents hydrogen or an aryl group substituent; are useful for the affinity binding of a prion protein.

Abstract: The present invention relates to cationic lipids capable of forming complexes with nucleic acids and the use thereof for the transfection of eukaryotic cells. The cationic lipids according to the invention have general formulas (I) and (Ia): (see formulas (I) and (Ia), wherein E is a heteroaryl; R1 and R2 are selected from H, —R7—NH2, alkyl; R7 is selected from alkyl, alkenyl, aryl, (C1-C20) alkyl-aryl-(C0-C20) alkyl; R3 and R4 are selected from: H, —R8—SH, R8—NH—NH2/—R8—CO—R9 or —R8—NH2; R8 is selected from: alkyl, alkenyl, aryl, (C1-C20) alkyl-aryl-(C0-C20) alkyl; R9 is selected from: H, alkyl; R5 and R6 are selected from: H, alkyl, alkenyl, aryl, (C1-C20) alkyl-aryl.

Abstract: The invention describes novel compositions that include a cross linking compound, a polymer and a 1 nm to about a 25 micron sized particle optionally with an oxide layer. In particular, the particle is a silica and one which has been pretreated with a silane.

Abstract: The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance having at least one amino group is reacted with an alcohol in a reaction mixture in the presence of ammonia.

Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.

Abstract: The invention relates to a method for producing a compound having at least one mono substituted amino group. According to the invention, a starting substance supporting at least one amino group as reacted with a reagent supporting a first functional group and at least one other functional group in a reaction mixture. The first functional group is a hydroxyl group and the at least one other functional group is selected from hydroxyl groups, mercapto groups, carboxylic acid groups, carboxylic acid ester groups, carboxylic acid amide groups, keto groups, carbonate groups, halogens, epoxy groups and carbamate groups. If several other functional groups are present, the groups are selected independently of one another from the aforementioned class. Melamine, urea and guanamine are, in particular, reacted with glycol, glycerine and hydroxyl acetic acid derivatives.

Abstract: A melamine skeleton-bearing organosilicon compound has a film forming ability, water solubility and compatibility with resins. It is prepared by reacting cyanuric chloride with a primary and/or secondary amine compound and neutralizing with a base.

Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Abstract: The present invention relates to triazine derivatives of the general formula (I), their use and production.

Abstract: The present invention relates to an electrodepositable coating composition comprising a crater control additive.

Abstract: A process for the production of leather using one or more reaction products of (a) triamines or higher amines with (b) at least one compound of the general formula I A1-R1??I where R1 is selected from hydrocarbon radicals having 10 to 5000 carbon atoms, straight-chain or branched, saturated or having from one to three C—C double bonds, and A1 from groups capable of reacting with amines.

Abstract: The invention describes novel crosslinking compounds that include photoactivatable moieties. Several families of compounds are disclosed that can include one or more hydrophilic moieties that help to solubilize the compounds in aqueous environments.

Abstract: The present invention relates to new triazine DNA modifiers, pharmaceutical compositions thereof, and methods of use thereof

Abstract: Trisubstituted triazines can be synthesized from cyanuric chloride. These compounds are useful anti-tubulin agents for treating cancer and proliferative diseases.

Abstract: A compound of formula (A): wherein L1 and L2 each independently are a single bond or a divalent linking group, R1 and R2 each independently are a hydrogen atom or a substituent, and R is a group having a polymerizable group; and a composition, containing at least one of the compound; an optically anisotropic material, containing the compound or the composition; and a liquid crystal display device, containing the optically anisotropic material.

Abstract: The present invention relates to unsymmetrical and symmetrical phosphorus-comprising heptazine derivatives, represented by the formula (1): in which Ra, Rb and Rc are, independently of one another, an azide group —N3 or an —N?PR1R2R3 group, with the proviso that at least one radical from Ra, Rb and Rc is an —N?PR1R2R3 group, to a process for the preparation thereof and to the use thereof.

Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.

Abstract: New triazine derivatives containing carbamate groups, processes for preparing them, and their use.

Abstract: Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

Abstract: In a process for preparing alkoxycarbonylaminotriazines, di- or triaminotriazines are reacted with cyclic carbonic esters and optionally with minor amounts of acyclic carbonic esters in the presence of an alcohol and of an alkali metal alkoxide or alkaline earth metal alkoxide as a base.

Abstract: Provided are a composition for thermosetting organic polymeric gate insulating layer and an organic thin film transistor using the same. The composition for thermosetting organic polymeric gate insulating layer contains a thermosetting material in polyvinyl phenol as an organic polymeric gate insulating layer material, to improve a chemical resistance and an insulating property, and an organic thin film transistor includes a thermosetting organic polymeric gate insulating layer formed of the composition. The composition for thermosetting organic polymeric gate insulating layer endows an organic polymer with a thermosetting property, thereby being capable of improving the chemical resistance and the insulating property as well as of forming a layer having a device property improved.

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.

Abstract: The invention relates to the use of enaminotriazines of the formula I in which the radicals Y, independently of one another, are hydrogen, an optionally substituted aliphatic, cycloaliphatic, araliphatic or aromatic radical having in each case up to 18 carbon atoms, the radicals X are identical or different, where at least one of the radicals X is the ethenyl radical of the formula II and X may also have the meanings of Y, and where in the formula II the radicals R are identical or different and are cyano, optionally esterified carboxyl, substituted carbonyl, optionally substituted aminocarbonyl, optionally esterified sulfo, substituted sulfonyl or optionally esterified phosphono, and where two adjacent radicals R may optionally form a ring and the radicals R? are identical or different and are hydrogen, an optionally substituted aliphatic, cycloaliphatic or aromatic radical having in each case up to 18 carbon atoms, as UV filters in cosmetic or pharmaceutical preparations for protecting human skin o

Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: There are described triazine derivatives of formula (1), wherein R1 is an unsubstituted or mono- or poly-hydroxy-, C1-C18 alkyl-, C1-C18 alkoxy-, amino-, C1-C5 monoalkylamino- or di-C1-C5 alkylamino-substituted C1-C18 alkyl, C2-C18 alkenyl, C6-C10 aryl or C6-C10 heteroaryl radical; unsubstituted or C1-C5 alkyl-substituted C5-C7 cycloalkyl or C5-C7 cycloalkenyl; —OR?; or —NR?R?; R2 is hydrogen; an unsubstituted or mono- or poly-hydroxy-, C1-C18 alkoxy-, cyano-, amino, C1-C5 monoalkylamino- or di-C1-C5 alkylamino-substituted C1-C18 alkyl, C2-C18 alkenyl; C6-C10 aryl or C6-C10 heteroaryl radical; —OR?; or —NR?R?; or R1 and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring; A is C1-C5 alkyl; an unsubstituted or hydroxy-, C1-C18 alkyl- or C1-C18 alkoxy-substituted C6-C10 aryl or heteroaryl radical; or a radical of formula (1a); R? and R? are each independently of the other hydrogen; unsubstituted or mono- or poly-hydroxy-, halo-, C1-C18 alkyl-, C1-C18 alkoxy-, amino- or quaternary ammonium group

Abstract: The present invention provides a process for preparing N-methylated melamines in simple steps by using inexpensive raw materials in such a manner that the proportion of mono-type, bis-type and tris-type of the N-methylated melamines as prepared can be controlled. The process comprises reacting by heating melamine with methylamine in the presence of an acidic catalyst under pressure to substitute at least one amino group of the melamine by methylamino group.

Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: Mixtures of triazine derivatives free from polyalkylene oxide Mixtures of triazine derivatives free from polyalkylene oxide are produced from 20 to 70 percent by weight of triazine derivatives with hydroxyalkyl amino groups and 80 to 30 percent by weight of triazine derivatives with bis(hydroxyalkyl) imino groups by catalytic reaction of alkylpropylene oxides with triazine derivatives at a melamine derivative/alkylpropylene oxide molar ratio of 1:1.5 to 1:10 in the presence of metal alkyls, metal hydrides, metal alcoholates and/or metal alkylamides as catalysts. The triazine derivative/hydroxy group mixtures free from polyalkylene oxide are particularly suited for producing plastic materials, flame retardants, additives, pharmaceuticals, textile auxiliaries, and paints or finishes.

Abstract: Polymers are prepared from A) 60 to 95 percent by weight of a mixture including A1) 20 to 70 percent by weight of hydroxyalkyl amino triazines and A2) 30 to 80 percent by weight of bis(hydroxyalkyl) amino triazines B) 5 to 40 percent by weight of polyfunctional compounds selected from one or more of B1) polyisocyanates and/or oligomeric polyesters or polyethers with isocyanate end groups, B2) aliphatic dicarboxylic acids, esters, chlorides or anhydrides, or aromatic polybasic acids, esters, chlorides or anhydrides, B3) aliphatic or aromatic diglycidal compounds or triglycidyl compounds, and, optionally, C) 1 to 20 percent by weight of aliphatic, cycloaliphatic or aromatic dihydroxy compounds, polyalkylene glycols and aliphatic aldehydes.

Abstract: The present invention discloses an active-hydrogen-containing phosphorus compound for cross-linking a resin and for imparting flame-retardancy to the cured resin, and in particular to a cured frame-retardant epoxy resin prepared by reacting the hardener with a di- or poly-functional epoxy resin via an addition reaction between the active hydrogen and the epoxide group. The present invention also discloses an epoxy resin made from the active-hydrogen-containing phosphorus compound and epihalohydrin.

Abstract: Heterocyclic tin compounds, useful as flame retardants and/or as smoke suppressants for halogen-containing polymers, e.g., polyvinyl chloride resins having application as wire and cable coatings, are obtained by reacting a trisubstituted triazine such as melamine with a tin-containing compound such as tin tetrachloride.